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ABSTRACT 
Background  
Clostridium difficile Infection (CDI) is one of the common health problems worldwide. 
Prevention techniques require fast and precise detection with high sensitivity. Conventional 
diagnostic methods are time-consuming, costly and inappropriate for clinical field settings. 
Therefore, the aim of this study is to develop Gold Nanoparticles- based assay (AuNPs) for 
direct qualitative detection of the nucleic acid of C.difficile and its toxins. The proposed assay is 
expected to be highly sensitive, rapid and simple. 
Methods  
Total one hundred five C.difficile isolates were collected from Al-Khor hospital (a member of 
Hamad Medical Corporation). Results of Clostridium difficile isolates were confirmed by RT-
PCR (GeneXpert, Cepheid, CA, USA). Different concentration of salts and different annealing 
temperature were all developed and optimized. Extracted DNA, hybridization buffer containing 
salt and a primer were mixed. The mixture was heated, annealed and then cooled to room 
temperature for 10 minutes followed by the addition of AuNPs. C.difficile toxins were also tested 
using the same AuNPs optimization. 
Results  
One hundred five positive C.difficile isolates were tested using the optimized AuNPs based-
assay. In ninety-six samples out of one hundred five, the color of the solution changed from red 
to blue within 1 min, which is considered a positive result. On the other hand, there were no 
color change in nine samples out of 105 and were considered as negative.  All Ninety-six 
positive samples were positive for Toxin B by RT-PCR (GeneXpert, Cepheid, CA, USA) and 
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AuNPs assay. Six samples were positive for binary toxins by RT-PCR (GeneXpert, Cepheid, 
CA, USA). However, binary toxins results using AuNPs assay were positive for all samples. 
Conclusion  
Our study showed a sensitivity of 91.4 % and a specificity of 100%. Furthermore, C.difficile 
toxins were tested using AuNPs, and it showed 100 % agreement with toxin B detection in 
comparison to RT-PCR (GeneXpert, Cepheid, CA, USA). However, the assay results were not 
compatible with RT-PCR (GeneXpert, Cepheid, CA, USA) results of Binary toxins. Further 
work is needed to improve the assay efficiency for detection of Binary Toxins and to validate the 
assay on clinical samples. 
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Chapter 1- Introduction 
Communicable diseases represent one of the main causes of morbidity and mortality in the 
developing and developed countries with significant financial burden. The huge expansion of the 
world population and global travel has influenced their spread from one area to another in the 
world, making them one of the major worldwide health threats. Prevention techniques against 
those diseases mandate fast and precise detection and identification of the pathogenic organisms 
with highest sensitivity. Traditional diagnostic methods are time-consuming, costly and 
inappropriate for field conditions. Nano diagnostic assays have been promising for timely, 
sensitive, point-of-care and cost-effective detection of microbial agents (Hauck et al., 2010).  
Clostridium difficile (CDF) is a significant health problem around the world. The prolonged 
incubation period of this agent before the development of clinical manifestations, makes the 
diagnosis and patient management challenging. Clostridium difficile is the most significant 
reason of nosocomial diarrhea (Dalpke et al., 2013). It is responsible for the majority of cases of 
infectious antibiotic-associated diarrhea (AAD) as well as pseudomembranous colitis that may 
result in death (Pancholi et al., 2012) 
Gold has been an exciting material in nanotechnology and has been discovered to be a crucial 
diagnostic material. Gold nanoparticles (AuNPs) display a wide range of uses among NPs based 
assays for microbial detection and identification. Distinctive size-dependent optical properties of 
AuNPs, their inertness and strength make them one of the most robust materials utilized in Nano 
diagnostics (Syed, 2014). 
Localized Surface Plasmon Resonance (LSPR) is one of the most significant criteria of gold 
nanoparticles (Au NPs). Because of these natural optical properties, colloidal solutions of Au 
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NPs have high extinction factors and diverse color in the visible area of the spectrum when they 
are well-spaced in comparison with when they are aggregated. Accordingly, a generally 
composed substance connection between the analyte and NPs surroundings prompts a change of 
color (red to blue from spread out to aggregated ones, respectively) permitting the visual 
recognition of the target analyte (Vilela et al, 2012).  Moreover, this sort of colorimetric assays 
has established significant consideration in the analytical field on account of their effortlessness 
and low cost since they do not require any costly or sophisticated instrumentation. As a result of 
this, recognition of molecules with a high importance in the bio-medical and clinical fields 
including DNA, proteins and a wide range of organic and inorganic molecules have been 
impressively reported in the most relevant literature utilizing these assays (Vilela et al., 2012) 
Aim & Objectives  
The aim of this project is to develop Gold Nanoparticles- based assay for direct qualitative 
detection of the nucleic acid of CDF and its toxins from leftover preserved isolates. Moreover, to 
evaluate Sensitivity, Specificity for Gold Nanoparticles in CDF detection compared to RT-PCR 
(GeneXpert, Cepheid, CA, USA).   
Hypothesis 
Using Gold Nanoparticles for the detection of CDF will meet demands of the clinical 
laboratories to improve sensitivity and specificity compared to Real Time- Polymerase Chain 
Reaction (PCR). The proposed assay is expected to be highly sensitive, rapid, simple and 
minimize the need for expensive and sophisticated equipment.  
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Chapter 2- Literature review 
2.1. Clostridium difficile 
Clostridium difficile (CDF) is a Gram-positive, strictly anaerobic, spore-forming bacterium 
(Chankhamhaengdecha et al., 2013). It was first isolated in 1935 by Hall and O'Toole from 
newborn feces and meconium and was originally named Bacillus difficile because of its 
morphology and difficulty in cultivation (Burnham & Carroll, 2013). It was considered normal 
flora until late 1970s where it was recognized to be responsible for most cases of antibiotic-
associated diarrhea (AAD) and was quickly expanding in prevalence (Goncalves et al., 2004). 
Clostridium difficile infection (CDI) is a major clinical and infection control issue in numerous 
health care facilities (Pancholi et al., 2012). This organism is carried asymptomatically in about 
50% of neonates, 20% of hospitalized patients and only 2% of healthy adults. In fact, 
asymptomatic carriers usually exceed symptomatic patients. Therefore, the high level of healthy 
carriers among hospitalized patients coupled with the presence of patients under antibiotic 
treatment explains the high rate of nosocomial diarrhea associated with CDF (Belanger et al., 
2003).  
2.1.1. Prevalence and incidence 
CDF is responsible for 10%-35% of AAD and nosocomial diarrhea that is associated with high 
morbidity and mortality and this subsequently leads to health care system burden. For example, 
the estimated annual cost in the USA is approximately 3.2$ billion where 80% of CDI is a 
hospital acquired infection (HAI) while 20% is a community-acquired infection (CAI) (Khan et 
al., 2014).  
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The prevalence of CDI in Qatar is 7.9%. This prevalence is comparable to data from other 
Middle-Eastern countries (prevalence range 4.6- 13.7%; average ~8.6%) (Al-Thani et al., 2014) 
The incidence of CDI in the USA, Canada, and Europe increased among long term and elderly 
(older than 65 years) hospitalized patients. It has been found that the overall incidence in these 
countries ranges from 2 to 6 cases per 10,000 patients days (Khan et al., 2014). On the other 
hand, it has been found that the overall incidence in Qatar was 1.6 cases/10,000 patient days.  
2.1.2. Toxins and their contributed genes                                                                                                
CDF produces two major toxins that are toxin A (enterotoxin) and toxin B (cytotoxin). Toxins A 
and B are glucosyltransferases that are encoded by the genes TcdA and TcdB, respectively, and 
inactivate Rho- family within target cells. Release of toxins inactivates Rho- family and other 
GTPases, affecting their interactions with regulatory molecules and interrupting vital signaling 
pathways. Cells round up, shrink, and die, leading to significant loss of the intestinal epithelial 
barrier, and tight junctions are disrupted, permitting neutrophil migration. In addition, both 
toxins stimulate the release of pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor 
necrosis factor-alpha (TNF), and IL-8 from activated macrophages. This subsequently leads to 
neutrophil recruitment, stimulating an inflammatory response; neutrophil aggregation is 
responsible for the pseudomembrane formation seen in severe colitis (PMC) (Burnham et al., 
2013). 
CDF toxin A and toxin B are located with three more genes (TcdC, TcdR, TcdD) on the CDF 
chromosome in a 19.6-kb pathogenicity locus (PaLoc) only present in pathogenic strains 
(Persson et al., 2011). TcdC and TcdD encode negative and positive regulators respectively that 
control the level of toxin production and TcdE facilitate toxin release from the bacterial cell wall 
(Luna et al., 2011). Most pathogenic strains are toxin A-positive, toxin B-positive (A+B+) strains 
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although toxin A-negative, toxin B-positive (A-B+) variant isolates have been emerged as 
pathogenic strain according to the literature (Sambol et al., 2000). Diverse genetic alterations in 
the TcdC gene have been observed. Most prominent are the in-frame deletion of 18, 39, or 54 bp 
and the mutation at position 117 (1-bp deletion) (Persson et al., 2011). Some strains of CDF also 
secrete an actin-specific ADP-ribosyltransferase called CDT or binary toxin. These binary toxins 
are encoded by two genes (cdtA and cdtB) and are located outside the PaLoc (Goncalves et al., 
2004).  
Figure 2.1.1: Genetic map of toxin loci in Clostridium difficile. (a) Structure of the 
pathogenicity locus (PaLoc). Toxin genes are shaded in green, regulatory genes are in red, 
tcdE is in blue. (b) Structure of CdtLoc (binary toxin locus). Toxin and regulatory genes 
are shaded in green and red, respectively.  
 
2.1.3. Pathophysiology                                                                                                                                                 
CDF is a major nosocomial pathogen causing CDI and life-threatening PMC (Eastwood et al., 
2009). The pathogenic effects of CDF are mucosal damage to the colon that is caused by toxin A 
and toxin B (Sambol et al., 2000). Mature colonic bacterial flora in a healthy adult is resistant to 
CDF colonization. However, if the normal colonic flora is altered due to antibiotic as an 
example, resistance to colonization is lost (Eastwood et al., 2009). Following the colonization, an 
enterotoxin, TcdA, which is found in ~70% of C.difficile strains and a cytotoxin, TcdB, which is 
found in all CDF strains, can be produced, thereby disrupting tight junctions of the intestinal 
epithelial cells resulting in inflammation and increased permeability of the intestine. Once spores 
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are ingested via contact or environment, their acid-resistance allows them to pass through the 
stomach intact, grow and multiply into vegetative cells in the colon upon exposure to bile acids. 
This cause colonization in immunosuppressed patients and production of toxins (Carter et al., 
2007). As a results of these effects, polymorph nuclear neutrophils (PMNs) are recruited to the 
site of toxin action and lead to PMC (Voth & Ballard, 2005). Approximately less than 10% of 
clinical CDF isolates possess binary toxins (cdtA/B), which have been associated with increased 
severity of the symptoms. The pathogenic role of cdtA (enzymatic component) and cdtB 
(Binding component) has been suggested to trigger microtubule protrusion, thereby increasing 
the adherence of CDF to the gut epithelium (Chankhamhaengdecha et al., 2013).  
2.1.4. Clinical features 
CDF causes a spectrum of clinical presentation ranges from mild, self-limiting diarrhea to 
serious Pseudomembranous Colitis (PMC) and toxic megacolon, leading to colonic perforation, 
peritonitis, and even death. Symptoms occur secondary to the production of two major toxins, 
toxin A and toxin B, which affect the integrity of the colonic mucosa (Tenover et al., 2010). The 
Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America 
(SHEA/IDSA) guidelines define severe disease as colitis associated with a leukocyte count that 
is 15,000 cells/ L or higher. Other characteristics include markedly elevated temperature 
reaching 40°C, PMC, and hypoalbuminemia (serum albumin level of 2.5 mg/dl). Fulminant C. 
difficile occurs in 5% of patients and is characterized by severe abdominal pain, profuse diarrhea, 
or sometimes no diarrhea, as the patient rapidly progresses to development of an ileus or toxic 
megacolon (Burnham  et al., 2013). 
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2.1.5. Diagnosis 
The diagnosis if CDI is based on the clinical features, Laboratory confirmation for the presence 
of toxins in stool and sometimes endoscopy to verify PMC (Sambol et al., 2000). Since CDI rate 
is increasing rapidly in health care facilities and to implement timely infection control measures 
and appropriate patient management, a rapid and reliable identification of toxigenic CDF is 
necessary. However, laboratory diagnostics remain challenging, as rapid test procedures relying 
on enzyme immunoassays (EIAs) show limited sensitivity, whereas the more-sensitive (94%-
100%) and more accurate (99%-100%) toxigenic culture and cytotoxicity assays which are 
considered as “gold standard” are time-consuming (long turnaround time), high cost and requires 
tissue culture facilities (Dalpke et al., 2013). EIA for testing TcdB alone or both TcdA/B offer a 
simple, rapid turnaround time (TAT) compared to conventional methods, tests for which the time 
to the final result can be 2 to 6 h. However, EIA is associated with reduced sensitivity (65%- 
85%) and specificity (95% - 100%), with performance largely dependent on which reference 
method is used for comparison, making its reliability questionable for an accurate diagnosis of 
CDI (Pancholi et al., 2012). Enzyme immunoassay (EIA) for CDF Glutamate dehydrogenase 
(GDH) antigen is used to detect the presence of the enzyme GDH, which is produced by all 
strains of CDF isolates (toxigenic and non-toxigenic). This method is highly sensitive (75%-
90%) with high Negative Predictive Value (NPV) (95%-100%) but is not specific (≤ 50%) with 
low Positive Predictive Value (PPV) for toxigenic isolates; therefore, a 2-step method has been 
recommended by the Infectious Diseases Society of America/ Society for Healthcare of America 
guidelines (SHEA/IDSA) on diagnostic testing of CDF. This strategy uses GDH and then uses 
RT-PCR as the confirmatory test for GDH-positive stool samples. Recently, Nucleic acid 
amplification techniques (NAATs) for CDF testing have been developed to combine low 
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turnaround times with high sensitivity, nevertheless they are expensive, require skilled personnel 
and the platforms and ease of use vary considerably, fully automated PCR assays that combine 
nucleic acid extraction, amplification, and detection have been developed. Currently, there are a 
number of FDA-approved commercially available NAATs including (i) the Xpert C.difficle, (ii) 
the illumigene C.difficile assay (Dalpke et al., 2013). These methods have high sensitivity (88%- 
100%) and high specificity (96%- 100%). These assays detect conserved regions of toxin A 
(tcdA) or B (tcdB) genes located on the pathogenicity locus (PaLoc) of C. difficile. For 
epidemiological studies, positive C. difficile isolates are further analyzed by PFGE, PCR-
ribotyping, and/or direct sequencing of the tcdC gene to detect the 18-bp or nt 117 deletions 
(Pancholi et al., 2012). 
Prior to performing Laboratory tests, abdominal imaging studies, including CT scans, may reveal 
“thumbprinting” of colonic mucosa, which suggests the presence of mucosal edema, but these 
changes are not specific for PMC due to CDF. Direct visualization of colonic mucosa using 
either sigmoidoscopy or colonoscopy is required to determine the presence of PMC. However, 
CDF colitis or diarrhea may occur without pseudomembrane formation, and colitis may be 
missed if only proximal disease is present. In general, sigmoidoscopy and colonoscopy should be 
avoided in fulminant colitis because of the risk of toxic megacolon and perforation (Sambol et 
al., 2000) 
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Table 2.1.1: Laboratory diagnostic tests used for C.difficile detection. Different methods 
vary in sensitivity, specificity and turnaround time (Khan et al., 2014) 
 
Laboratory test Sensitivity (%) Specificity (%) Turnaround time 
(TAT) 
Tissue culture cytotoxicity assay 94-100 99-100 1-3 days 
Glutamate dehydrogenase enzyme assay 75-90 <50 15-45 minutes 
Enzyme immunoassay for C.difficile toxin 65-85 95-100 2-6 hours 
RT-PCR (Cepheid GeneXpert) 88-100 96-100 45 minutes- 1 hour 
Anaerobic culture of stool 89-100 48-68 2-3 days 
 
2.1.6. Treatment  
CDI treatment often involves the first line treatment that is discontinuation of antibiotics if 
deemed to be medically appropriate and providing appropriate supportive care with hydration 
and electrolyte replacement. For mild disease, this is often sufficient for full recovery. For more 
severe disease, antimicrobial therapy directed against CDF is essential. Empirical treatment with 
oral metronidazole for two weeks is suggested. Vancomycin for two weeks as well is the 
recommended second-line treatment.  
2.1.7. Preventive measures 
Prevention of CDI is challenging health authorities. However, preventive measures are taken 
such as implementation of infection-control measures (careful attention to hand washing, 
Patient’s isolation, barrier precautions (PPE), and cleaning of the physical environment with 10% 
hypochlorite solution throughout the duration of symptomatic disease (Okada, 2010). Because 
CDF spores may be, relatively resistant to alcohol, current and comprehensive guidelines 
recommend that health care workers wash their hands with soap and water. Strategies aimed at 
preventing the development of CDF diarrhea include antibiotic restriction, the use of probiotics 
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and passive and active immunization (Halsey, 2008). A multidisciplinary antibiotic management 
program to restrict the inappropriate use of antibiotics can lead to a significant decrease in HAI 
caused by CDF.  
2.2. Gold Nanoparticles (AuNPs): 
Nanotechnology has been promising for the development of rapid, accurate and cost-effective 
tool for the next generation of diagnostic assays with high sensitivity (Kaittanis et al., 2012).  
There are many types of Nanoparticles (e.g., Ag, ZnO, Co etc.) considered toxic to human and 
not used for in vivo applications. Nevertheless, Gold has low toxicity and is safe to be used in in 
vivo applications (Syed et al., 2011). The use of AuNPs to label with DNA was first discovered 
by Mirikin et al. in 1996. He added thiol group (-SH) to one end of the DNA probe since it has a 
strong affinity to gold. In 2009, Liandris et al. have designed AuNPs based assay for 
Mycobacterium DNA detection. In 2010, Uludag and coworkers had developed a biosensor for 
Herpes Simplex 1 virus (HSV-1) and DNA probe conjugated with AuNPs was used to hybridize 
with the target DNA.  
Because of AuNPs unique optical and physiochemical properties, they have many applications in 
medicine, material sciences, imaging, therapeutics as well as diagnostics (Cai et al., 2008). Gold 
nanoparticles (AuNPs) exhibit a broad spectrum of applications among NP based assays for 
microbial detection and identification and among the most promising nanoparticles. They are 
gold spheres with a typical diameter of approximately 2- 100 nm. Gold nanoparticles (AuNPs) 
exhibit a unique phenomenon known as Localized Surface Plasmon Resonance (LSPR), which is 
responsible for their intense red color. This color changes to blue upon aggregation of AuNPs 
that are easily detected visually without the aid of any instrumentation. The addition of salt 
shields the surface charge on the AuNPs, which are typically negatively charged due to reduced 
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citrate ions on their surfaces leading to aggregation of AuNPs and red-to-blue color change 
(Syed, 2014). The above mentioned unique optical properties have allowed the use of AuNPs in 
simple and rapid colorimetric assays for clinical diagnosis that can offer simpler, faster, cheaper 
and reliable detection techniques for CDF. Development of such tests would support global, 
regional efforts to control CDF in developing countries with limited resources and high infection 
rates (Syed, 2014). 
The principle of this assay is that citrate-coated AuNPs possess a surface negative charge which 
allows the adsorption of single-stranded DNA (ssDNA), which can uncoil and expose their 
nitrogenous bases, allowing electrostatic attraction to the AuNPs surface. Consequently, the 
negative charge on the AuNPs increases and so does the repulsion between the AuNPs, thus 
preventing their aggregation. Upon addition of AuNPs to a saline solution containing the target 
nucleic acid and its complementary target, and this double-stranded DNA structure cannot 
adsorb on AuNPs due to the repulsion between its negatively-charged phosphate backbone and 
the negatively-charged coating of citrate ions on the surface of the AuNPs. In this situation, 
primers are not free to stabilize the AuNPs and the solution color changes to blue, due to 
aggregation of AuNPs. On the other hand, in the absence of the target or the presence of a non-
complementary target, the aggregation of the AuNPs is prevented due to the presence of free 
primers to stabilize them, and solution color remains red (Figure 2.2.1).  
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Figure 2.2.1: Principle of colorimetric AuNPs-based assay in microbial identification. If the 
primer is complementary to the DNA/RNA target, there will be no free primers in the 
mixture leading to aggregation of AuNPs and blue color formation. On the other hand, if 
primer is not complementary to the target, it will be free in the mixture and binds to 
AuNPs preventing aggregation and the color remains unchanged  (Shawky et al., 2010) 
 
 
 
 
 
DNA 
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Several studies had been published on the application of AuNPs in microbial detection. One 
study was conducted and published by Shawky et al., 2010 in the detection of Hepatitis C virus 
(HCV). Another study using AuNPs in the detection of Mycobacterium Tuberculosis Complex 
(MTBC) was published by Hussein et al., 2013. Recent studies in Acinetobacter baumanni 
identification also showed a high sensitive and accurate results compared to conventional 
biochemical methods and PCR (Khalil et al., 2014). Furthermore, a study was done on the 
identification of E.coli using AuNPs oligo-prob principle, and it was found that it is highly 
sensitive and specific (Padmavathy et al., 2012). Several studies on Intestinal organisms 
detection using Gold nanoparticles has been published. For example, In 2008, Wang and his 
team develop a quartz crystal microbalance (QCM) biosensor for real-time detection of E. coli 
O157:H7 DNA based on nanogold particles amplification and results showed that this developed 
biosensor enhance the detection of E.coli O157:H7 compared to conventional method (Wang et 
al., 2008). Staphylococcus aureus is also one of the most important human pathogens, causing 
more than 500,000 infections in the US each year. By using aptamers that specifically recognize 
S. aureus, Chang et al. (2013) developed an ultrasensitive aptamer-conjugated AuNPs for rapid 
bacterial detection. Their non-polymerase chain reaction (PCR)-based method measures the 
resonance light-scattering signal of aptamer-conjugated AuNPs to detect a single cell within 1.5 
h. Accordingly to the authors this platform technology has the potential to develop a rapid and 
sensitive bacterial testing at point-of-care (Veigas et al., 2014). This new assay also had been 
currently developed and validated to provide faster and at a low cost diagnosis of resistant 
pathogens (MRSA, MDR-TB & XRD-TB) comparing to conventional culture and drug 
susceptibility tests (Veigas et al., 2014).  
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Intestinal pathogens detection were developed using Gold nanoparticles to detect salmonella 
infection. It was conducted by Kalidasan et al., 2013 and showed that it is promising and 
sensitive method. One study related to C.difficile detection in 2013 in which Luo et al. had 
developed an aptamer biosensor for the detection of toxin A of Clostridium difficile using gold 
nanoparticles synthesized by Bacillus stearothermophilus.  The results of the study showed good 
sensitivity in the detection of toxin A as well as good selectivity, stability ad recovery rate (Luo 
et al., 2014). Furthermore, many examples of different approaches of AuNPs-based assays for 
microbial detection and identification were discovered and evaluated. One of these methods is 
immunochromatographic strips. The principle of this assay is that gold is conjugated with 
antibodies impregnated in membrane chromatography. They are commercially available and 
have been developed to detect several viruses, bacteria, fungi and parasites (Syed et al., 2011). 
Moreover, AuNPs had been integrated in many assays to enhance sensitivity and specificity for 
example, Bio Barcode Based (BBB) Assays for Microbial DNA Detection (Syed et al., 2011). 
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Chapter 3: Material and Methods 
Ethical consideration 
This study was approved by Hamad Medical Corporations (HMC) Research Office, Doha, Qatar, 
Research Protocol #11136/11: "NPRP-4-1215-3-317 Gold Nanoparticles-based Assays for 
Direct and Cost Effective Detection of High Burden Diseases." See Appendix (1) 
Collection of bacterial isolates: 
Leftover CDF isolates cultured stool samples originally provided for regular clinical analysis 
were collected from Hamad Medical Corporation- Al Khor Hospital in Doha, Qatar, during the 
period of 2011 to 2012. One hundred forty-eight (148) Cryopreserved Clostridium difficile 
isolates were revived and sub-cultured onto Blood Agar enrichment medium and incubated 
anaerobically. Forty-three (43) CDF isolates were excluded from the study either due to 
duplication or failure of the strains to grow. One hundred five (105) samples were transported to 
QU (Health Science Department- Biomedical Research Center) in an icebox for extraction and 
testing with Gold Nanoparticles based assay. The isolated CDF were confirmed previously using 
RT-Polymerase Chain Reaction (PCR) (GeneXpert, Cepheid, CA, USA). Another method is the 
morphology of feathery spreading colonies on enrichment media, which is the characteristic 
feature of CDF.  According to PCR results, all CDF isolates were positive for toxin B and 6 were 
positive for Binary toxin along with toxin B. 29 additional ATCC Bacterial Strains other than 
CDF and Clostridium species were used to assess specificity performance and cross-reaction. 
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DNA Extraction: 
Genomic DNA from bacterial cultures (Sheep Blood Agar plate cultures) was extracted using 
QIAamp DNA Mini Kit (Qiagen; Cat. No.51306) according to manufacturer's instructions. 
Briefly, culture cells was suspended in 180 µl of Buffer ATL (Supplied in the QIAamp DNA 
Mini Kit) into 1.5 ml centrifuge tubes by vigorous stirring and then 20µl of Proteinase K was 
added and mixed by vortexing, then was incubated at 560C. The tube was centrifuged to remove 
drops from the inside of the lid. After that, four µl of RNase A (100 mg/ml) was added and 
mixed by pulse-vortexing for about 15 seconds, incubation was done for 2 minutes at room 
temperature and then centrifuged briefly. After that 200 µl Buffer AL was added to the sample, 
mixed again by pulse-vortexing for 15 seconds and incubated at 700C for 10 minutes. The tube 
was centrifuged briefly to remove drops from inside the lid. After that, 200 µl ethanol (96-100%) 
was added to the sample and mixed by pulse-vortexing for 15 seconds. After mixing, the tube 
was centrifuged briefly to remove drops from inside the lid. The lysate (including the precipitate) 
was transferred carefully onto QIAamp Spin Column without wetting the rim of this column that 
contain a filter to remove all the debris except the DNA of the bacteria. Centrifuge at 6000 x g 
(8000 rpm) for 1 minute was done, and the QIAamp Spin Column was transferred to a clean 2 ml 
collection tube, the collection tube containing the filtrate was discarded. Then 500 µl Buffer 
AW1 was added, centrifugation at 6000 x g (8000 rpm) for 1 min was done and the QIAamp 
Spin Column was transferred to a clean 2 ml collection tube, the collection tube containing 
filtrate was discarded. Later 500 µl of AW2 buffer was added, centrifuge at full speed 12000 x g 
(14000 rpm) for 3 min to dry the column. Next, the QIAmp Spin Column was transferred to a 
clean 1.5 ml microcentrifuge tube; the collection tube containing filtrate was discarded. Finally, 
centrifuge at 6000 x g (8000 rpm) for 1 min was done. 
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Measurement of DNA concentration using Spectrophotometer: 
All the extracted DNA samples were measured for DNA concentration and purity by 
spectrophotometer technique using Infinite F200 PRO (TECAN) and 260/280 ratios were 
calculated automatically (data not shown).  
DNA Restriction using Bam HI 
Extracted DNA was restricted using Promega kit. In 1.5 ml microcentrifuge tube, a mixture was 
prepared by adding 2 µl Buffer (10x), 0.2 µl Acetylated BSA, 10 µl DNA Samples and 0.5 µl 
enzyme (Bam HI). To adjust the final volume to 20 µl 7.3 µl of free DNase water was added. 
Mixing gently by pipetting was done; the tube was centrifuged for a few seconds in a 
microcentrifuge, and then incubated at 370C for 1 hour and at 650C for 15 minutes.  
Restricted DNA Precipitation 
For DNA precipitation; 2 µl of (3M sodium acetate) was added to 20 µl of restricted DNA; and 
22 µl of isopropanol. Then the mixture was incubated for 30 minutes in the freezer and 
centrifuged at 13000 rpm for 30minutes. After that, the supernatant was discarded carefully, and 
20 µl of Nuclease-Free water was added. Finally, the DNA is either stored at -200C or at -800C 
for long term storage. 
Amplification of Clostridium difficile by PCR:  
To detect the CDF DNA in preserved isolates, we have carried out the conventional PCR assay 
as follows: 12.5 µl PCR Master Mix was combined with 1.25 µl of each forward CD-F (5’- 
 GTG CGG CTG GAT CAC CTC CT- 3’) and reverse CD-R (5’- CCC TGC ACC CTT AAT 
AAC TTG ACC- 3’) primers. Then 2.5 µl of precipitated DNA template and 1.25 µl Dimethyl 
sulfoxide (DMSO, Promega) were added. Finally, the mixture was made up to 25 µl volume with 
Nuclease-Free water (6.25 µl). The PCR amplification was initiated at 950C for 2 minutes and 
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completed by 30 amplification cycles (denaturation at 950C for 30 seconds, annealing at 500C for 
30 seconds and extension at 720C for 0.45 seconds and final elongation at 720C for 2 minutes). 
PCR amplification was carried out in ABI 9700 GeneAmp PCR System (Applied Biosystems) 
Gel Electrophoresis (GE): 
To confirm the quality of C.difficile DNA, Gel electrophoresis was run. First 1:10 buffer (Tris 
borate) was prepared by taking 100 ml of Tris/ borate buffer and dilute with distilled water to 
have a final volume of 1000 ml. After that 2 g of agarose gel was dissolved in 100 ml diluted 
buffer and kept in the oven until completely dissolved. Then was left to cool down at room 
temperature and 2µl ethidium bromide was added. CDF DNA Samples (10 µl after mixing with 
2 µl dye) were loaded as well as a ladder (6 µl of 100 bp) at 100 voltage for 45 minutes. Then the 
result was read by gel imaging device using (BIO-RAD).  
Synthesis of AuNPs: 
Spherical AuNPs were prepared by citrate reduction of hydrogen tetrachloroaurate (III) 
(HAuCl4.3H2O). Briefly, the reflux system was cleaned by aqua regia (1 Nitric Acid: 3 HCL) 
and then rinsed with ultrapure water, and blown out with N2. First working solution was prepared 
as following: 1 mM Gold Chloride (20 ml from 10mM stock to 200 ml de-ionized water) and 
38.8 mM Sodium Citrate (9.7 ml from 200mM stock to 50 ml de-ionized water). An aqueous 
solution of 50 ml of 1 Mm HAuCl4.3H2O was brought to reflux while stirring. Then cover the 
Gold Chloride containing beaker with aluminum foil and place in the sand bath so that it’s fully 
immersed in sand. Later place 10 ml of 38.8mM sodium citrate in a 15 ml falcon tube and place 
it in a water-filled beaker, in the sand bath. When the Gold-Chloride starts to boil, 10 ml sodium 
citrate (1% trisodium citrate) was added quickly which resulted in a change in solution color 
from yellow to clear to black to purple to dark red. Afterward, the solution will be refluxed for an 
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additional 15 minutes and then allowed to cool to room temperature. The colloidal solution will 
then transferred to a clean storage bottle. The concentration of the trisodium acetate in the 
reaction will determine the final AuNPs size i.e. as the concentration of sodium acetate 
decreases, the AuNPs size increases. See Appendix (II) 
Au weight (?) =  = = 0.0197g = 19.7mg in 50ml 
Characterization of AuNPs: 
The absorbance of the prepared AuNPs solution was measured by spectrophotometry. The 
recommended AuNPs size ranges from 12-15 nm with the absorbance of the visible range 400-
700nm (Shawky et al., 2010) (Hussain et al., 2013). The AuNPs average size was measured by 
Zetasizer Nano ZSP (Malvern, UK). It is used for the characterization of proteins and 
nanoparticles. The system incorporates a two angle particle and molecular size analyzer for the 
enhanced detection of aggregates and measurement of small or dilute samples, and samples at 
very low or high concentration using dynamic light scattering with ‘NIBS’ optics. Dynamic 
Light Scattering (DLS) is used to measure particle and molecule size. DLS measures the 
diffusion of particles moving under Brownian motion, and converts this to size and a size 
distribution using the Stokes-Einstein relationship. Non-Invasive Back Scatter technology 
(NIBS) is incorporated to give the highest sensitivity simultaneously with the highest size and 
concentration range. Brownian motion principle suggests that the movement of particles is due to 
the random collision with the molecules of the liquid that surrounds the particle. The ZSP also 
incorporates a zeta potential analyzer that uses electrophoretic light scattering for particles, 
molecules, and surfaces.  
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Colorimetric AuNPs assay for detection of CDF DNA: development and optimization 
Optimization of Colorimetric Qualitative AuNPs Assays for C. difficile was done through 
optimization of the assay parameters such as annealing temperature, salt concentration and 
targeting oligonucleotide sequences. 
Different concentrations of NaCl and primer concentrations were tested to determine the 
optimum concentrations for performing the assay (Appendix IV). Hybridization buffer was 
prepared using 0.50 M NaCl and 10 μM primer. Different volumes of the AuNPs were tested 
(data not shown), and 25 μL of the prepared AuNPs (12-15 nm) was selected for use in the final 
assay. As for the primer used in the assay, reverse CD-R (5’- CCC TGC ACC CTT AAT AAC 
TTG ACC- 3’) was used due to its high specificity to all CDF. The assay was performed as 
follows, 22 μL of the extracted DNA were placed in a sterile PCR tube and 13 μL of the 
hybridization buffer (4.8 ul NaCl + 5.4 ul primer + 2.8 ul Nuclease-Free Water) were added and 
mixed well (final concentration of the primer and NaCl after addition of AuNPs was 0.9 μM and 
0.04 M, respectively) to have a final concentration of 35 ul per PCR tube. The mixture was then 
heated at 95 °C for 30 s and annealed at 50 °C for 30 s and then cooled to room temperature for 
10 min. 25 μL of colloidal AuNPs were then added to the mixture, and the color was observed 
within 1 min. (Shawky et al., 2010). Positive, negative control and E.coli were run with every 
run. Positive control tube contains (4.8 ul NaCl + 30.2 ul Nuclease-Free Water) while negative 
control tube contains (4.8 ul NaCl + 5.4 ul primer + 24.8 ul Nuclease-Free Water). 
While cell culture cytotoxicity assays have been considered the “gold standard” historically, 
there is no currently universally agreed upon gold standard for toxigenic C. difficile detection. In 
this study, we consider RT-PCR (GeneXpert, Cepheid, CA, USA) as our “reference method” 
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since it is the method used in the clinical laboratory in Qatar as confirmatory assay for CDF 
detection. 
Assay performance assessment 
The following performance parameters of the developed AuNPs assays will be determined then 
compared to (RT-PCR) (GeneXpert, Cepheid, CA, USA) to evaluate the developed assays: 
1. Specificity 
Using the following formula 
Specificity= True negative (TN)/ True negative (TN) + False positive (FP) X 100 
 
To measure specificity, a total of 29 enteric bacterial organisms, consisting of ATCC organisms 
(Bacteroides fragilis ATCC 25285; Campylobacter jejuni ATCC 33291; Clostridium perfringens 
ATCC 13124; Escherichia coli ATCC 35218, ATCC 25922, and O157: H7 ATCC 35150; 
Enterococcus faecalis ATCC 29212; Enterobacter aerogenes ATCC 13048; Klebsiella 
pneumoniae ATCC 700603; Peptostreptococcus anaerobius ATCC 27337; Proteus mirabilis 
ATCC 12453; Proteus vulgaris ATCC 13315; Pseudomonas aeruginosa ATCC 27853; and 
Salmonella typhi ATCC 14028, Shigella flexeneri ATCC 12022, Brevibacillus agri ATCC 
51663, Enteropathogenic E.coli type (2, 3 & 4), Hafnia species, Yersinia enterocolitica ATCC 
27729, Stenotrophomonas maltophilia ATCC 51331, Vibrio cholera, Candida albicans ATCC 
90028 ,  Staph.aureus ATCC 29213, Staph. epidermidis ATCC 12228, Staphylococcus 
saprophyticus ATCC 15305, Streptococcus pyogenes ATCC 19615 and Streptococcus 
agalactiae ATCC 12386 were individually analyzed by TaqMan PCR. In brief, each organism 
was cultured into Blood agar medium, and Genomic DNA was extracted from isolated colonies, 
restricted, precipitated, PCR and GE. DNA purity and quantity were measured by absorbance 
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spectrophotometry. In specificity formula, True negative samples are those which are negative 
with RT-PCR (GeneXpert, Cepheid, CA, USA and AuNPs-based assay. While False positive 
samples are those which are negative by RT-PCR (GeneXpert, Cepheid, CA, USA) and positive 
by AuNPs-based assay 
2. Sensitivity 
Using the following formulas: 
Sensitivity= True positive (TP)/ True positive (TP) + False negative (FN) X 100 
 
To measure Sensitivity, the results of AuNPs based assay were compared with RT-PCR 
(GeneXpert, Cepheid, CA, USA) which is considered in this study as “Gold standard” since it is 
the method used in Clinical Microbiology Laboratory for C.difficile detection with high 
sensitivity and specificity. In sensitivity formula, True positive samples are those which are 
positive with RT-PCR (GeneXpert, Cepheid, CA, USA) and AuNPs-based assay. While False 
negative samples are those which are positive by RT-PCR(GeneXpert, Cepheid, CA, USA) and 
negative by AuNPs-based assay 
Gold Nanoparticles assay to detect CDF toxins:  
CDF isolates were used to detect tcdB, as well as cdtA and cdtB genes. Same optimization was 
used but with Toxin B (Tcd B) primer (5- CAC GCC TGG AGA ATC TAT ATT TGT AGA 
AA-3) and binary toxins (cdtA & cdtB) primers cdtA (5- ATG CAC AAG ACT TAC AAA GCT 
ATA GTG-3) & cdtB (5- CCA AAA TTT CCA CTT ACT TGT GTT G -3) to detect different 
CDF toxins.  
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Statistical analysis  
Excel program was used for simple calculations (Frequencies, percentage, mean and standard 
deviation of the age). Sample characteristics including age, gender, clinical findings and 
nationality were summarized using frequency distributions to generate the numbers and 
percentages (Table 4.1)  
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Chapter 4: Results 
4.1. Demographics and clinical diagnosis characteristics of the study population 
In this study, a total of 105 cryopreserved (leftover) CDF isolates were collected Hamad Medical 
Corporation- Al-Khor Hospital, Doha, Qatar.  
Table 4.1 shows demographic data in 105 cases including nationality, gender, age and clinical 
data using frequency distributions to generate the numbers and percentages. The majority of 
patients were elderly (≥ 50 years) and most of them suffer from diarrhea (49.5%) 
The age range was 1-95 years with a mean age of 46 years and Standard deviation of 27.2, 
61.9% were males and 38.1% were females. The distribution of patients based on their age 
groups < 10, 10-30, 31-50, and ≥50 was 17 (16.2%), 18 (17.1%), 16 (15.2%) and 54 (51.4%) 
respectively. Total 38.1% of the patients in the sample population were Qataris and 61.9 % were 
non-Qataris. Twenty-three patients 23 (21.9 %) were addmitted to the hospital with fever, 52 
(49.5 %) with diarrhea, 1 (0.95 %)  with gastrointestinal bleeding and 37 (35.2 %) have no 
clinical data record. 
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Table 4.1: Demographic data of the study population. Demographic data in 105 cases 
including nationality, gender, age and clinical data 
Variable Category No. Of subjects 
n (%) 
Total number of 
subjects 
Qatari residents 
Non-Qatari 
40 (38.1 %) 
65 (61.9 %) 
Gender      Males   
Females      
65 (61.9 %) 
40 (38.1 %) 
Age <10 yrs 
10-30 yrs 
31-50 yrs 
≥ 50 yrs 
17 (16.2%) 
18 (17.1 %) 
16 (15.2 %) 
54 (51.4 %) 
Clinical data  Diarrhea 
Fever 
GI Bleeding 
No data 
52 (49.5 %) 
23 (21.9 %) 
1 (0.95 %) 
37 (35.2 %) 
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4.2. Characterization of AuNPs: 
the absorbance of the synthesized Gold Nanoparticle solution  was measured by 
spectrophotometry using a visible light wavelength of 400-700 nm. The graph below (Figure 4.1) 
shows the absorbance vs. wavelength of the synthesized colloidal gold nanoparticles solution 
prepared in our laboratory. The peak represents the AuNPs λmax which was within 518-521 nm 
that is considered suitable for testing (Shawky et al., 2010).  
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Extinction spectra of the prepared AuNPs solution. It displays the peak in the 
visible light region with λmax 518-521 nm 
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After that, the average size of AuNPs was measured using Zetasizer Nano ZSP (Malvern, UK) 
via DLS. The peak represents the size distribution by number (percent) and it was within range 
12-15 nm (Hussain et al., 2013) (Figure 4.2).   
 
 
 
 
 
 
 
 
 
Figure 4.2: AuNPs size measurement using Zetasizer Nano ZSP (Malvern, UK). The peak    
represents the number (percent) of AuNPs that have size within 12-15 nm 
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4.3. CDF Gold Nanoparticles assay prototype: 
The AuNPs-based assay is affected by four main factors that should be optimized for best results. 
These factors are concentrations of NaCl, AuNPs and primer used, and the assay annealing 
temperature. As indicated in chapter 3, the optimized AuNPs-based assay had been initially 
developed for the detection of CDF isolates. The assay was performed as follows, 22 μL of the 
extracted DNA were placed in a sterile PCR tube and 13 μL of the hybridization buffer (4.8 μL 
NaCl + 5.4 μL primer + 2.8 μL Nuclease-Free Water) were added to have a final concentration 
of 35 ul per PCR tube. The mixture was then heated at 95 °C for 30 s and annealed at 50 °C for 
30 s. after cooling the mixture at room temperature for 10 minutes, 25 μL of 12-15nm AuNPs 
were then added. The photograph was taken within 1 minute from the addition of the AuNPs. 
Note the change in color from red to blue in the positive samples (Figure. 4.3 A and B). Blue 
color indicates the presence of primers complementary to the CDF DNA sequence and this leads 
to the aggregation of AuNPs together. On the other hand, red color indicates that the primer is 
free in the mixture that will bind to AuNPs and prevent their aggregation. Any minimal change 
in color from red to blue or purple is considered positive results.  
96 out of 105 CDF positive samples gave a blue color and 9 out of 105 gave a red color (Table 
4.2). Negative samples were retested and yielded the same results (Figure 4.3 C). E.coli ATCC 
25922 was used as a negative control.  
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Figure 4.3: AuNPs-based assay for C.difficile detection (Qualitative). Positive control (+ctr) 
= blue, Negative control (-ctr) = red. E.coli ATCC 25922 as negative control= red. A) All 
CDF samples were positive (change in color from red to blue). B) All CDF samples were 
positive (blue color) except 36, 61 & 68. Negative samples were retested and yielded the 
same results as seen in Figure C.  
 
 
A 
B 
C 
B 
C 
Control C.difficile isolates 
C 
C.difficile isolates 
Control 
  +ctr  –ctr  E.coli   16     17     19     20     24     22          31     39     44     47     48       49    50     51 
 
 
     52     53     57     59      62     65     70     71         
 
+ctr   –ctr    E.coli  
 
   34     35   36    40   41   42    43    54      60   61   64   67    68    80    81   82 
 
     36                 61                  68  
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29 ATCC Strains of Clostridium species and other than Clostridium difficile were also tested for 
AuNPs and all samples were negative (red color) to measure specificity and cross reaction 
(Figure 4.4 A, B and C).  
 
Figure 4.4: AuNPs based assay for other than Clostridium difficile and other Clostridium 
species (Qualitative)(A-C). Positive control (+ctr) = blue, Negative control (-ctr) = red. All 
samples were negative (red color). E.coli ATCC 25922 as negative control= red. BF: 
Bacteroides fragilis, Pepto.: Peptostreptococcus anaerobious and Camp.: Campylobacter 
jejuni.  
 
 
 
 
C 
B A
 
Control 
Control 
Control 
Control 
Non C.difficile isolates 
Non C.difficile isolates 
 +ctr  –ctr  E.coli    4    5      6      7       8        9     10    11    12   13   14   15   16      
 
17   18   19    20      
 
        +ctr        -ctr        E.coli      BF      Pepto.  Camp. 
+ctr    –ctr            E.coli     23       24         25        26        27        28        29     
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4.4. Assay performance assessment: 
Based on the above results, the AuNPs-based assay performance has been assessed in 
comparison to the results of RT-PCR (GeneXpert, Cepheid, USA) using simple statistical 
formula of sensitivity and specificity. 
 
Sensitivity= True positive (TP)/ True positive (TP) + False negative (FN) X 100 
= 96/ (96+9) X 100= 91.4% 
 
Specificity= True negative (TN)/ True negative (TN) + False positive (FP) X 100 
= 29/ (29+0) X 100= 100% 
 
These initial results showed that the assay has a sensitivity of 91.4 % and a specificity of 100% 
in comparison to RT-PCR (GeneXpert, Cepheid, USA) (Table 4.2). Initially, no cross-reactivity 
was observed between C.difficle and other bacteria tested (Figure 4.4). 
 
Table 4.2: AuNPs-based assay performance results of C.difficile isolates.  96 out of 105 
positive C.difficile samples were positive using AuNPs-based assay. As a result, the new 
developed assay has a sensitivity of 91.4% compared to RT-PCR.  29 ATCC strains non 
C.difficile were negative by AuNPs-based assay compared to RT-PCR and the new 
developed assay has a specificity of 100 %  
Samples Real time PCR AuNPs Assay 
C.difficile positive 105 96 (91.4%) 
C.difficile negative 29 29 (100%) 
Total 134 125 
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4.5. Gold Nanoparticles assay to detect CDF toxins  
All CDF positive samples with AuNPs were tested for toxins by AuNPs. Same optimization for 
the hybridization buffer (4.8ul NaCl + 5.4 ul primer + 22 ul CDF extracted DNA + 2.8 Nuclease-
Free Water) was used in the CDF toxins detection but using specific Toxin B (Tcd B) primer (5- 
CAC GCC TGG AGA ATC TAT ATT TGT AGA AA-3) & binary toxin cdtA primer (5- ATG 
CAC AAG ACT TAC AAA GCT ATA GTG-3) & cdtB primer (5- CCA AAA TTT CCA CTT 
ACT TGT GTT G -3). Ninety-six samples were positive for toxin B using the optimized AuNPs 
assay and same result when using RT-PCR (GeneXpert, Cepheid, USA) (Figure 4.5).  For the 
binary toxin, only 6 samples were positive out of 96 samples using the RT-PCR. However, all 
AuNPs assay tested samples (96) were positive for the binary toxin (Figure 4.6). Clostridium 
perfringens ATCC 13124 was used as a negative control in toxins detection with AuNPs. 
 
 
 
Figure 4.5: AuNPs based assay for C.difficile toxin B detection (Qualitative). Positive 
control (+ctr) = blue, Negative control (-ctr) = red, Clost.: C.perfringens ATCC 13124 and 
E.coli ATCC 25922 as negative control= red. All samples were positive (blue color).   
Control 
C.difficile isolates toxin B positive 
+ctr  –ctr  Clost. E.coli 65  67   70   71          72   73   74   75   76    80    81   82        
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Figure 4.6: AuNPs based assay for C.difficile Binary toxins (cdtA & cdtB) detection 
(Qualitative). Positive control (+ctr) = blue, Negative control (-ctr) = red, Clost.: 
C.perfringens ATCC 13124 as negative control= red. All samples were positive (blue color). 
Samples (7, 24, 35, 85, 131 & 137) were positive for binary toxins by RT-PCR (GeneXpert, 
Cepheid, USA). Other samples were negative for Binary toxins but positive for Toxin B by 
RT-PCR. 
 
 
 
 
 
 
 
 
Control C.difficile isolates binary toxin positive 
+ctr  -ctr   Clost.  7     12    24    30     35         51    80    85     97   107  131  137  148 
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Chapter 5: Discussions 
Clostridium difficile (CDF) is a significant health problem in hospital and community 
acquired infection. It is responsible for the majority of cases of infectious antibiotic-associated 
diarrhea (AAD) as well as pseudomembranous colitis (PMC) which may result in death (Dalpke 
et al., 2013). The use of the appropriate antibiotic therapy is crucial to prevent the progression of 
C.difficile pathogenesis. Thus, the rapid diagnosis of this pathogen is crucial in patient’s 
management and Infection control surveillance (Okada, 2010). The incidence of C. difficile 
infection (CDI) is increasing throughout the world with the universal use of antibiotics (Okada, 
2010). Several diagnostic tools for the detection of this pathogen in clinical microbiology 
laboratories are available. Although widely used and very rapid, conventional diagnostic 
methods are time-consuming, costly and inappropriate for clinical field settings. Although RT-
PCR has many advantages to overcome problems with the conventional methods and to be used 
as standalone method, it had some disadvantages that affect its use worldwide for example, it is 
expensive, require sophisticated infrastructure and skilled staff (Khalil et al., 2014). In contrast, 
nanodiagnostics assays have been promising for timely, sensitive, point-of-care and cost-
effective detection of microbial agents (Hauck et al., 2010). Therefore, the aim of this study was 
to develop Gold Nanoparticles- based assay (AuNPs) for direct qualitative detection of the 
nucleic acid of CDF and its toxins.  
Currently in Clinical laboratories in Hamad Medical Corporation, C.difficile is detected 
using 2-step algorithm as suggested by CDC SHEA/IDSA. This strategy uses Glutamate 
Dehydrogenase (GDH) as screening test because of its high sensitivity and then uses the RT-
PCR (GeneXpert, Cepheid, USA) as confirmatory test for GDH-positive stool samples only. 
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In this study, isolated CDF strains were originally confirmed by RT-PCR (GeneXpert, 
Cepheid, USA) in clinical laboratory (Al-Khor Hospital). Negative and positive controls were 
first run to optimize the assay conditions before testing CDF isolates. Optimized AuNPs-based 
assay was developed for detection and identification of CDF, which includes the extracted DNA 
from colonies followed by detection of CDF and their toxins using specific primers and colloidal 
AuNPs solution. 
The AuNPs-based assay is affected by four main factors: annealing temperature, size of 
AuNPs, primers and salt concentrations. Of these, the constant parameter in this study was the 
AuNPs size. Control of the particles size was achieved by using the suitable concentration of the 
sodium citrate, which acts as reducing agent. This citrate reduction causes the AuNPs to be 
negatively charged. The remaining factors were optimized for detection of CDF. High annealing 
temperatures can result in AuNPs aggregation. However, in this assay, AuNPs is added after the 
annealing step, which enabled the use of optimal temperature for annealing without interference 
with AuNPs solution stability. Different primer concentrations were tested to stabilize the 
AuNPs colloidal in the presence of appropriate NaCl concentration (Hussain et al., 2013). In this 
study, the optimal concentration for the primer was found to be 0.9-1 µM in the total assay 
volume. Moreover, the optimal final concentration of NaCl used was 0.04 M that is sufficient for 
aggregation of AuNPs and visual detection of the color change.  
The principle of the AuNPs assay is based on the ability of ssDNA primers to stabilize 
the colloidal AuNPs preventing their salt-induced aggregation. In the positive sample (target 
present), primers will bind with their complementary DNA sequence in the target; therefore, 
addition of AuNPs will lead to its aggregation by the salt available in hybridization buffer, 
resulting in blue color development. On the other hand, if target is absent, ssDNA primers will 
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remain free in the solution, stabilizing colloidal AuNPs, preventing their salt-induced 
aggregation and maintaining the red color of the solution (Khalil et al., 2014). 
The initial AuNPs-based assay prototype was developed and optimized to detect CDF 
positive isolates and their toxins. The results showed a high sensitivity and specificity (91.4 % 
and 100% respectively) compared to RT-PCR. These initial results suggest that the new assay 
has a comparable performance to RT-PCR. False negative results can be due to very high 
concentration of the primer that will prevent aggregation of AuNPs. In contrast, very low 
concentration of the primer may cause false positive results.  The AuNPs assay detected toxin B 
in all 96 isolates identified as tcdB-positive by RT-PCR. These results declared complete 
concordance with RT-PCR results. On the other hand, Binary toxins were positive in 6 CDF 
isolates by RT-PCR assay, approximately 6 to 12.5% of strains of C. difficile produce binary 
toxin, which confirms the low prevalence of binary toxin. However all the samples (96) show 
positive results when was tested for Binary Toxin using AuNPs assay. This is may be related to 
the fact that the Binary Toxin is encoded by the Cdt locus (CdtLoc) (Burnham et al., 2013). It 
was found that there is a correlation between the presence of the PaLoc and the CdtLoc. More 
than 98% of CdtLoc-positive strains also have the PaLoc (Carter et al., 2007). Using other 
Binary primer sequences with more specificity for binary toxin Cdt locus could contribute to 
overcome the result interference. In our study, the overall agreement (accuracy) between the 
AuNPs-based assay and RT-PCR was 93.3%.  
The turnaround time for the developed assay was found to be 15-30 minutes, which is 
shorter than RT-PCR (45minutes- 1 hour). Moreover, the use of AuNPs eliminates the need for 
expensive detection instrumentation (Shawky et al., 2010). 
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Because of the high sensitivity and specificity of AuNPs-based assays for detection of 
nucleic acid targets, AuNPs based methods have been established for detection of several 
pathogenic organisms such as Mycobacterium tuberculosis (MTB), Hepatitis C virus (HCV), 
Methicillin Resistant Staphylococcus aureus (MRSA) and others. In comparison to several 
studies uses AuNPs in microbial detection and identification, results showed acceptable 
sensitivity and specificity in detecting HCV using AuNPs-based assay (93.3% and 88.9% 
respectively) (Shawky et al., 2010). Another study showed 96.6% sensitivity and 98.9% 
specificity for the detection of Mycobacterium tuberculosis Complex (MTBC) and 94.7% 
sensitivity and 99.6% specificity for the detection of MTB (Hussain et al., 2013). Recent studies 
in Acinetobacter baumanni identification also showed a high sensitive and accurate results 
compared to conventional biochemical methods and PCR (Khalil et al., 2014). Furthermore, a 
study was done on the identification of E.coli using AuNPs oligo-prob principle, and it was 
found that it is highly sensitive and specific (Padmavathy et al., 2012). Several studies on 
Intestinal organisms detection using Gold nanoparticles has been published. For example, In 
2008, Wang and his team develop a quartz crystal microbalance (QCM) biosensor for real-time 
detection of E. coli O157:H7 DNA based on nanogold particles amplification and results showed 
that this developed biosensor enhance the detection of E.coli O157:H7 compared to conventional 
method (Wang et al., 2008). Another study using Gold nanoparticles to detect salmonella 
infection was conducted by Kalidasan et al., 2013 and his collegue. It showed promising results 
and sensitive method (Kalidasan et al., 2013). One study related to C.difficile detection in 2013 
in which Luo et al. had developed an aptamer biosensor for the detection of toxin A of 
Clostridium difficile using gold nanoparticles synthesized by Bacillus stearothermophilus.  The 
results of the study showed good sensitivity in the detection of toxin A as well as good 
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selectivity, stability ad recovery rate (Luo et al., 2014). The use of gold nanoparticles for 
screening molecular signatures of drug resistance (MRSA, MDR-TB & XDR-TB) that has been 
reported thus far, and provides a critical evaluation of current and future developments of these 
technologies assisting pathogen identification and characterization (Veigas et al., 2014). MRSA 
detection using AuNPs with clinical samples demonstrated very good agreement with the “gold 
standard” (94.44%). In addition the sensitivity and specificity were 97.14% and 91.89% 
respectively compared to conventional standard method(Veigas et al., 2014).  
These results were consistent with the initial results that were obtained in this study 
except the detection of HCV using AuNPs showed low specificity (88.9%) compared to our 
study (100%). This is because clinical serum samples were used in this study.  
Current trends in Clostridium difficile detection involve using microarray. Hicke et al., 
2012 combine the advantages of molecular testing (sensitivity) and immunoassays (low cost) and 
developed an assay for toxigenic C. difficile that couples isothermal DNA amplification to array-
based hybridization using clinical samples. This idea can be implemented in AuNPs-based assay 
development since there is integration of specific primers (molecular) and colorimetric assay 
(immunoassay) to have a sensitive and cost effective method in the near future and could be used 
as Point of Care Testing (POCT).  
In this study, the AuNPs-based assay requires simple preparation and nucleic acid 
extraction. It does not require target amplification prior to detection, which reduces the cost, 
time, the need for highly trained staff and expensive and complex instrumentation along with 
providing high sensitivity and specificity. However, most of the work being carried out is in the 
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initial stage of development, and further simplification and commercialization of the assays are 
likely to be achieved soon.  
Although AuNPs showed acceptable sensitivity and specificity compared to RT-PCR, the 
limitations of this study is that C.difficile isolates tested is leftover isolates that may be prone to 
contamination or inability to grow. Another limitation is missing other diagnostic laboratory data 
that could be useful in the study. Further limitation of the study is that the assay is not yet 
validated on clinical stool samples. This AuNPs assay would have a significant impact especially 
in low-resource settings if it was tested with stool samples directly to evaluate Positive predictive 
value, Negative predictive value and other performance criteria. It is also recommended to have a 
quantitative measurement along with qualitative analysis. A future plan in the phase II of this 
study is to test clinical stool samples to determine the following performance parameters of the 
developed AuNPs assays: PPV, NPV, Linearity, Limit of Quantification and interference 
assessment. 
In conclusion, Clostridium difficile (CDF) is a significant health problem around the world. The 
need for simple, rapid and precise method for CDF detection is a critical step for appropriate 
therapy and infection control measures implementation. A colorimetric assay has been developed 
for rapid detection of CDF and their toxins using AuNPs-based assay. Direct detection of 
genomic DNA by colloidal AuNPs-based assay was performed on 105 clinical CDF isolates in 
addition to twenty-nine reference strains other than Clostridium difficile. The initial results for 
the developed AuNPs-based colorimetric assay were positive in Ninety-six and negative in nine 
samples. The assay maybe considered cost effective, sensitive, reliable and rapid that can 
compete with commercial immunoassays and RT-PCR methods as routine tests for the 
management of CDF patients. This colorimetric assay is the first unmodified AuNPs-based assay 
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for the detection of CDF. Our future prospectives include the development of an AuNPs 
quantitative prototype using Froster Resonance Energy Transfer (FRET). Quantitative analysis is 
very important for patient’s management and therapy. It is used in early diagnosis to find out the 
concentration of the pathogen and to determine if it is early or late infection. Moreover, 
quantitative assay is useful for monitoring therapy. If concentration of the organism is still high 
after treatment, this may indicate resistance pattern. However if the concentration decreases, it 
gives indication that patient is responding to therapy. In addition, a wide range of clinical 
features is considered for early diagnosis. Further to evaluate AuNPs-based assay detection limit 
on samples with serial dilution and finally to vlidate this developed assay on clinical samples to 
determine the following performance parameters of the developed AuNPs assays: PPV, NPV and 
Linearity and interference assessment. 
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Chapter 6: Conclusions 
Clostridium difficile Infection (CDI) is a worldwide health problem with the increase in 
antibiotic consumption and absence of antibiotic restriction and stewardship. Diagnosis of 
C.difficile (CDF) is considered crucial in patient management and infection control measures and 
surveillance. Several diagnostic methods are available but with some disadvantages for example, 
Real-time PCR method that is used for C.difficile detection has a high sensitivity and specificity 
but it is costly, requires skilled staff and complex infrastructure. Therefore the aim of this study 
is to develop Gold Nanoparticles- based assay for direct qualitative detection of nucleic acid of 
CDF and its toxins. The proposed assay is expected to be highly sensitive, specific, rapid, simple, 
and minimize the need for expensive and complex equipment. Based on the collected data and 
results, 96 out of 105 of C.difficile samples showed positive results while 9 samples showed 
negative results compared to RT-PCR. The sensitivity of AuNPs was 91.4% compared to RT-
PCR 88-100% while specificity was 100% compared to RT-PCR 96-100%. These results 
showed acceptable performance as an initial study for the AuNPs developed assay. 
A colorimetric assay has been developed using AuNPs for the direct qualitative detection of CDF 
in leftover (cryopreserved) isolates. The developed assay has several advantages including 
acceptable sensitivity, specificity and short turnaround time. This developed, optimized AuNPs-
based assay may improve the management of C. difficile infection and may lead to a more 
rational use of antibiotics, as the clinicians will rapidly obtain the clinical microbiology results. 
However, a large-scale clinical trial is needed to further validate this assay. Eventually this assay 
may have a great impact on clinical diagnosis in low-resources countries for patient’s 
management and infection control measures.  
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Appendix I: Ethical approval 
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Appendix II: AuNPs Synthesis in QU Research center 
Change in color from colorless or light yellow to brick red 
                                                                                                                                                                                                                                                                            
 
 
 
 
 
 
0.020 g of AuCl4 dissolved in 50 ml Distilled Water         Addition of 1% Tri-sodium citrate  
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Appendix III: ATCC Strains other than C.difficile used in AuNPs-based assay 
Organism name Assigned sample 
ID 
Organism name Assigned 
sample ID 
E.coli ATCC 25922 E.coli ATCC 25922 E.coli ATCC 35218  15 
Bacteroides fragilis ATCC 
25285 
1 Stenotrophomonas maltophilia 
ATCC 51331 
16 
Peptostrptococcus 
anaerobious  ATCC 27337 
2 Proteus vulgaris ATCC 13315 17 
Campylobacter jejuni ATCC 
33291 
3 Proteus mirabilis ATCC 12453 18 
Salmonella typhi ATCC 
14028 
4 Vibrio cholera (patient’s isolates) 19 
Brevibacillus agri ATCC 
51663 
5 Enterobacter aerogenes ATCC 
13048  
20 
Enteropathogenic E.coli 
(EPEC) 2 (patient’s isolates) 
6 Clostridium perfringens ATCC 
13124 
21 
Enteropathogenic E.coli 
(EPEC) 3 (patient’s isolates) 
7 Staph.aureus ATCC 29213  23 
Enteropathogenic E.coli 
(EPEC) 4 (patient’s isolates) 
8 Staphylococcus saprophyticus 
ATCC 15305  
24 
Hafnia species (patient’s 
isolates) 
9 Staph. epidermidis ATCC 12228  25 
Shigella flexeneri ATCC 
12022 
10 Streptococcus agalactiae ATCC 
12386  
26 
Klebsiella pneumonia ATCC 
700603 
11 Candida albicans ATCC 90028 27 
E.coli O157 ATCC 35150 12 Enterococcus faecalis ATCC 29212 28 
Pseudomonas aeruginosa 
ATCC 27853 
13 Streptococcus pyogenes ATCC 
19615 
29 
Yersinia enterocolitica ATCC 
27729 
14   
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Appendix IV: Different concentrations of salt and primer results in the 
development and optimization step 
NaCl: 
NaCl final concentration range from 0.04-0.08 M. Primer concentration and volume was fixed 
(1uM, 3 ul) 
2 ul NaCl (0.2 M) 
 
 
Primer volume change from 3 to 2.9 ul (NaCl volume 2 ul (0.2 M) 
 
 
2.5 ul NaCl (0.2 M) 
 
 
 
3 ul NaCl (0.2 M) 
 
 
 
 
         +     +       QC fail 
         +     +       QC fail 
        +              +   QC fail 
     +      +     QC fail 
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5 ul NaCl (0.2 M) 
 
 
 
2 ul NaCl (0.5 M) 
 
 
 
2.3 ul NaCl (0.5 M) 
 
 
 
2.4 ul NaCl (0.5 M) 
 
 
 
2.6 ul NaCl (0.5 M) 
 
 
 
 
                           QC fail            +    + 
        +      +       QC fail 
                                                                      +      +       QC fail 
                                                                    +      +       QC fail 
                                                       QC fail       +     +        
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3 ul NaCl (0.5 M) 
 
 
4.8 ul NaCl (0.5 M) + 5.4 ul primer 
 
 
 
 
 
 
 
 
 
 
 
 
QC fail    +      + 
           +           -       E.coli             
QC pass 
        
48 
 
Appendix V: Results of C.difficile sample in RT-PCR  
(GeneXpert, Cepheid, CA, USA) and Gold nanoparticles-based assay   
No. of 
specimens 
RT-PCR 
(GeneXpert, 
Cepheid, CA, 
USA) 
AuNPs-based 
assay 
No. of 
specimens 
RT-PCR 
(GeneXpert, 
Cepheid, CA, 
USA) 
AuNPs-based 
assay 
1 Positive  Positive 32 Positive Positive 
2 Positive  Positive 33 Positive Positive 
3 Positive  Positive 34 Positive Positive 
4 Positive  Positive 35 Positive Positive 
6 Positive  Positive 36 Positive Negative 
7 Positive Positive 39 Positive Positive 
9 Positive Positive 40 Positive Positive 
10 Positive Positive 41 Positive Positive 
12 Positive Positive 42 Positive Positive 
15 Positive Positive 43 Positive Positive 
16 Positive Positive 44 Positive Positive 
17 Positive Positive 47 Positive Positive 
19 Positive Positive 48 Positive Positive 
21 Positive Positive 49 Positive Positive 
24 Positive Positive 50 Positive Positive 
25 Positive Negative 51 Positive Positive 
26 Positive Positive 53 Positive Positive 
27 Positive Weak Positive 54 Positive Positive 
30 Positive Positive 57 Positive Positive 
31 Positive Positive 59 Positive Positive 
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67 Positive Weak Positive 103 Positive Positive 
68 Positive Negative 104 Positive Positive 
70 Positive Positive 105 Positive Positive 
71 Positive Positive 106 Positive Negative 
72 Positive Positive 107 Positive Positive 
73 Positive  Positive 108 Positive Positive 
74 Positive Positive 109 Positive Positive 
75 Positive Positive 112 Positive Positive 
76 Positive Positive 113 Positive Positive 
80 Positive Positive 115 Positive Positive 
81 Positive Positive 116 Positive Positive 
82 Positive Positive 117 Positive Positive 
83 Positive Positive 118 Positive Positive 
84 Positive Positive 120 Positive Positive 
85 Positive Positive 123 Positive Positive 
86 Positive Positive 125 Positive Positive 
87 Positive Positive 126 Positive Positive 
88 Positive Positive 127 Positive Weak Positive 
89 Positive Positive 128 Positive Positive 
90 Positive Positive 129 Positive Negative 
91 Positive Positive 131 Positive Positive 
93 Positive Positive 132 Positive Negative 
96 Positive Positive 133 Positive Negative 
97 Positive Positive 134 Positive Positive 
102 Positive Positive 135 Positive Positive 
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136 Positive Positive    
137 Positive Positive    
140 Positive Negative    
141 Positive Positive    
142 Positive Positive    
143 Positive Positive    
145 Positive Positive    
146 Positive Positive    
147 Positive Positive    
148 Positive Positive    
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Appendix VI: Results of C.difficile toxin B in RT-PCR  
(GeneXpert, Cepheid, CA, USA) and Gold nanoparticles-based assay   
 
Sample 
CDF ID # 
AuNPs-based 
assay 
RT-PCR 
(GeneXpert, 
Cepheid, CA, 
USA) 
 
Sample 
CDF ID # 
AuNPs-based 
assay 
RT-PCR 
(GeneXpert, 
Cepheid, CA, 
USA) 
Toxin B Toxin B Toxin B Toxin B 
1 Positive Positive 34 Positive Positive 
2 Positive Positive 35 Positive Positive 
3 Positive Positive 39 Positive Positive 
4 Positive Positive 40 Positive Positive 
6 Positive Positive 41 Positive Positive 
7 Positive Positive 42 Positive Positive 
9 Positive Positive 43 Positive Positive 
10 Positive Positive 44 Positive Positive 
12 Positive Positive 47 Positive Positive 
15 Positive Positive 48 Positive Positive 
16 Positive Positive 49 Positive Positive 
17 Positive Positive 50 Positive Positive 
19 Positive Positive 51 Positive Positive 
21 Positive Positive 53 Positive Positive 
24 Positive Positive 54 Positive Positive 
26 Positive Positive 57 Positive Positive 
27 Positive Positive 59 Positive Positive 
30 Positive Positive 60 Positive Positive 
31 Positive Positive 62 Positive Positive 
32 Positive Positive 64 Positive Positive 
33 Positive Positive 65 Positive Positive 
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67 Positive Positive 107 Positive Positive 
70 Positive Positive 108 Positive Positive 
71 Positive Positive 109 Positive Positive 
72 Positive Positive 112 Positive Positive 
73 Positive Positive 113 Positive Positive 
74 Positive Positive 115 Positive Positive 
75 Positive Positive 116 Positive Positive 
76 Positive Positive 117 Positive Positive 
80 Positive Positive 118 Positive Positive 
81 Positive Positive 120 Positive Positive 
82  Positive Positive 123 Positive Positive 
83 Positive Positive 125 Positive Positive 
84 Positive Positive 126 Positive Positive 
85 Positive Positive 127 Positive Positive 
86 Positive Positive 128 Positive Positive 
87 Positive Positive 131 Positive Positive 
88  Positive Positive 134 Positive Positive 
89 Positive Positive 135 Positive Positive 
90 Positive Positive 136 Positive Positive 
91 Positive Positive 137 Positive Positive 
93 Positive Positive 141 Positive Positive 
96 Positive Positive 142 Positive Positive 
97 Positive Positive 143 Positive Positive 
102 Positive Positive 145 Positive Positive 
103 Positive Positive 146 Positive Positive 
104 Positive Positive 147 Positive Positive 
105 Positive Positive 148 Positive Positive 
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Appendix VII: Results of C.difficile Binary toxins in RT-PCR  
(GeneXpert, Cepheid, CA, USA) and Gold nanoparticles-based assay   
 
 
Sample 
CDF ID # 
AuNPs-based 
assay 
RT-PCR 
(GeneXpert, 
Cepheid, CA, 
USA) 
 
 
Sample 
CDF ID # 
AuNPs-based 
assay 
RT-PCR 
(GeneXpert, 
Cepheid, CA, 
USA) 
Binary toxins 
(cdtA & cdtB) 
Binary toxins Binary toxins 
(cdtA & cdtB) 
Binary toxins 
1 Positive Negative 34 Positive Negative 
2 Positive Negative 35 Positive Positive 
3 Positive Negative 39 Positive Negative 
4 Positive Negative 40 Positive Negative 
6 Positive Negative 41 Positive Negative 
7 Positive Positive 42 Positive Negative 
9 Positive Negative 43 Positive Negative 
10 Positive Negative 44 Positive Negative 
12 Positive Negative 47 Positive Negative 
15 Positive Negative 48 Positive Negative 
16 Positive Negative 49 Positive Negative 
17 Positive Negative 50 Positive Negative 
19 Positive Negative 51 Positive Negative 
21 Positive Negative 53 Positive Negative 
24 Positive Positive 54 Positive Negative 
26 Positive Negative 57 Positive Negative 
27 Positive Negative 59 Positive Negative 
30 Positive Negative 60 Positive Negative 
31 Positive Negative 62 Positive Negative 
32 Positive Negative 64 Positive Negative 
33 Positive Negative 65 Positive Negative 
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67 Positive Negative 107 Positive Negative 
70 Positive Negative 108 Positive Negative 
71 Positive Negative 109 Positive Negative 
72 Positive Negative 112 Positive Negative 
73 Positive Negative 113 Positive Negative 
74 Positive Negative 115 Positive Negative 
75 Positive Negative 116 Positive Negative 
76 Positive Negative 117 Positive Negative 
80 Positive Negative 118 Positive Negative 
81 Positive Negative 120 Positive Negative 
82  Positive Negative 123 Positive Negative 
83 Positive Negative 125 Positive Negative 
84 Positive Negative 126 Positive Negative 
85 Positive Positive 127 Positive Negative 
86 Positive Negative 128 Positive Negative 
87 Positive Negative 131 Positive Positive 
88  Positive Negative 134 Positive Negative 
89 Positive Negative 135 Positive Negative 
90 Positive Negative 136 Positive Negative 
91 Positive Negative 137 Positive Positive 
93 Positive Negative 141 Positive Negative 
96 Positive Negative 142 Positive Negative 
97 Positive Negative 143 Positive Negative 
102 Positive Negative 145 Positive Negative 
103 Positive Negative 146 Positive Negative 
104 Positive Negative 147 Positive Negative 
105 Positive Negative 148 Positive Negative 
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Appendix VIII: Poster 
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 ملخص
 خلفية
من المشاكل الصحية المنتشرة عالميا.ً يشترط الكشف السريع والدقيق  eliciffid muidirtsolCالعدوى البكتيرية تعتبر 
يتطلب التشخيص الدقيق استخدام تقنيات مكلفة والتي تتطلب معدَات  ،للكائنات المسببة للمرض جودة عالية . بالإضافة إلى ذلك
صصة ذات تكلفة مرتفعة وتستغرق وقتا طويلا كما انها غير مناسبة لإعدادات الحقل السريرية. ولذلك، فإن الهدف من هذه متخ
الدراسة هو تطوير اختبار يتميز بتوفير الوقت وإمكانية الإعتماد عليه في العينات السريرية باستخدام قياس اللون والتألق 
السموم التي تفرزها. و  eliciffid muidirtsolCنوعي عن الأحماض النووية لبكتيريا لجزيئات النانو جولد وذلك للكشف ال
 ومن المتوقع أن يكون الإختبار الجديد ذات جودة عالية وبسيط ولا يستغرق وقتا ًطويلاً.
 الطرق
 -TR باستخداموتم تأكيد ايجابية العينات  تم جمع مائة وخمس عينات من مستشفى الخور (عضو في مؤسسة حمد الطبية)
وقد تم إعداد جزيئات النانو جولد المثلى من خلال استعمال تراكيز    . )ASU ,AC ,diehpeC ,trepXeneG( RCP
. بعد ذلك تم خلط الحمض النووي المستخرج من بكتيريا  )erutarepmet gnilaenna(مختلفة من الملح والمعالجة الحرارية 
المناسب. ثم تم تسخين المحلول وتبريده الى  remirpالأمثل الذي يحتوي على الملح ومع المحلول   eliciffid muidirtsolC
درجة حرارة الغرفة لمدة عشر دقائق تليها إضافة جزيئات النانو جولد. بالإضافة الى ذلك تم استعمال نفس جزيئات النانو جولد 
 .eliciffid muidirtsolCالمثلى في الكشف عن سموم 
 النتائج
المثلى وأظهرت  الإيجابية باستخدام فحص جزيئات النانو جولد eliciffid muidirtsolC  ر مائة وخمسة من عيناتتم اختبا
ستة وتسعين عينة من بين مائة وخمس عينات حيث تغير لون المحلول من اللون الأحمر إلى اللون العينات نتائج ايجابية ل
ئج سلبية وعدم تغير لون المحلول في تسع عينات.  أما بالنسبة  للسموم فقد من ناحية أخرى لوحظ نتاوالأزرق في دقيقة واحدة. 
 ,diehpeC ,trepXeneG( RCP -TRباستخدام فحص  Bكانت جميع العينات الإيجابية الستة والتسعون إيجابية ل للسم 
تة وتسعين عينة ايجابية و فحص جزيئات النانو جولد. بينما ست عينات إيجابية  للسموم الثنائية من بين س  )ASU ,AC
. ومع ذلك، كانت النتائج للسموم الثنائية باستخدام فحص  )ASU ,AC ,diehpeC ,trepXeneG( RCP -TRباستخدام 
 جزيئات النانو جولد إيجابية لجميع العينات.
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 الخاتمة
، تم اختبار السموم  . وعلاوة على ذلك٪ 001وخصوصية الفحص كان  ٪ 4.19النتائج أظهرت أن تخصصية الإختبار كان 
 RCP -TRبالمقارنة مع  Bمع الكشف عن السم  ٪ 001باستخدام جزيئات النانو جولد، حيث أظهرت اتفاق  eliciffid.C
 -TR. ومع ذلك، فإن نتائج الفحص بالنسبة للسموم الثنائة كانت غير متوافقة مع  )ASU ,AC ,diehpeC ,trepXeneG(
. وبالتالي فإن هناك حاجة إلى مزيد من العمل ل تحسين كفاءة الفحص )ASU ,AC ,diehpeC ,trepXeneG( RCP
 للكشف عن ثنائي السموم كما أن الأختبار الجديد يتطلب تجربته على عينات سريرية مباشرة للمرضى.
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